World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
65436
World Ranking
8726
National Ranking
259

Overview

Markus P. Schlaich is affiliated with the University of Western Australia in Australia. Their research primarily focuses on medicine, with a significant emphasis on cardiology and cardiovascular medicine. Other notable fields of study include surgery, endocrinology, diabetes and metabolism, civil and structural engineering, and nutrition and dietetics.

The scientist's main research topics include blood pressure and hypertension studies, heart rate variability and autonomic control, cardiovascular health and disease prevention, sodium intake and health, hormonal regulation and hypertension, cardiovascular syncope and autonomic disorders, and diabetes treatment and management.

Publications by Markus P. Schlaich span several venues, with frequent contributions seen in:

  • Journal of Hypertension
  • Hypertension
  • European Heart Journal
  • Heart Lung and Circulation
  • Journal of the American College of Cardiology

Collaborations are an important aspect of their work. Frequent co-authors include:

  • Aletta E. Schutte
  • Janis M. Nolde
  • Revathy Carnagarin
  • Krzysztof Narkiewicz
  • George S. Stergiou

Recently published papers demonstrating their research contributions are:

  • Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial, 2022, The Lancet
  • 2020 International Society of Hypertension Global Hypertension Practice Guidelines, 2020, Hypertension
  • 2020 International Society of Hypertension global hypertension practice guidelines, 2020, Journal of Hypertension
  • May Measurement Month 2019, 2020, Hypertension
  • SGLT2 Inhibitor-Induced Sympathoinhibition, 2020, JACC Basic to Translational Science

Best Publications

  • Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

    Christopher J.L. Murray;Christopher J.L. Murray;Christopher J.L. Murray;Aleksandr Y. Aravkin;Aleksandr Y. Aravkin;Aleksandr Y. Aravkin;Peng Zheng;Peng Zheng;Peng Zheng;Cristiana Abbafati;Cristiana Abbafati;Cristiana Abbafati

  • Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

    Valery L Feigin;Benjamin A Stark;Catherine Owens Johnson;Gregory A Roth

  • 2020 International Society of Hypertension global hypertension practice guidelines.

    Thomas Unger;Claudio Borghi;Fadi Charchar;Nadia A Khan

  • Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial

    Murray D. Esler;Henry Krum;Paul A. Sobotka;Markus P. Schlaich

  • Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

    Henry Krum;Markus Schlaich;Robert Whitbourn;Paul Sobotka

  • Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

    Markus P. Schlaich;Paul A. Sobotka;Henry Krum;Elisabeth Lambert

  • Renin-angiotensin system and cardiovascular risk

    Roland E Schmieder;Karl F Hilgers;Markus P Schlaich;Bernhard M W Schmidt

  • Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension A Pilot Study

    Felix Mahfoud;Markus Schlaich;Ingrid Kindermann;Christian Ukena

  • Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

    Markus P. Schlaich;Elisabeth Lambert;David M. Kaye;Zygmunt Krozowski

  • Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study

    Henry Krum;Markus P Schlaich;Paul A Sobotka;Michael Böhm

  • Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy

    Markus P. Schlaich;David M. Kaye;Elisabeth Lambert;Marcus Sommerville

  • Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial

    Murray D Esler;Henry Krum;Markus Peter Schlaich;Roland E Schmieder

  • Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension

    Felix Mahfoud;Bodo Cremers;Julia Janker;Britta Link

  • Sympathetic Activation in Chronic Renal Failure

    Markus P. Schlaich;Flora Socratous;Sarah Hennebry;Nina Eikelis

  • Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept

    Markus P. Schlaich;Paul A. Sobotka;Henry Krum;Robert Whitbourn

  • Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension

    Felix Mahfoud;Christian Ukena;Roland E. Schmieder;Bodo Cremers

  • Renal Denervation in Moderate to Severe CKD

    Dagmara Hering;Felix Mahfoud;Antony S. Walton;Henry Krum

  • Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome

    Alicia A. Thorp;Markus P. Schlaich

  • Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant Hypertension

    Dagmara Hering;Elisabeth A. Lambert;Elisabeth A. Lambert;Petra Marusic;Antony S. Walton

  • Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications

    Gavin William Lambert;Nora Straznicky;Elisabeth A Lambert;John Dixon

Frequent Co-Authors

Murray D. Esler
Murray D. Esler Baker IDI Heart and Diabetes Institute
Gavin W. Lambert
Gavin W. Lambert Swinburne University of Technology
Roland E. Schmieder
Roland E. Schmieder University of Erlangen-Nuremberg
Henry Krum
Henry Krum Monash University
Michael Böhm
Michael Böhm Saarland University
David M. Kaye
David M. Kaye The Alfred Hospital
Paul J. Nestel
Paul J. Nestel Baker IDI Heart and Diabetes Institute
Mark Hamer
Mark Hamer University College London
Luis M. Ruilope
Luis M. Ruilope European University of Madrid
Karlheinz Peter
Karlheinz Peter Baker IDI Heart and Diabetes Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering Medicine in the USA, there are several online degree options and alternative career pathways worth exploring. Many choose nursing as a flexible entry point, especially since there are affordable nursing programs available entirely online. These programs offer a strong foundation in clinical knowledge and patient care while allowing students to balance studies with other responsibilities.

Those with an RN license can pursue advancement with the cheapest rn to bsn program options. This pathway equips nurses with enhanced skills and opens doors to higher-paying roles. For career changers or graduates from non-nursing backgrounds, direct entry msn programs offer a fast-track route into advanced nursing positions.

If you aim for leadership or academic roles, consider online phd nursing programs. These degrees allow professionals to contribute to research, policy, and teaching. Each pathway offers flexibility, affordability, and distinct career outcomes for those passionate about healthcare.

Best Scientists Citing Markus P. Schlaich

Trending Scientists

Recently Published Articles